What is Daxxify?
Another brand new toxin is about to hit the market! US company Revance has announced FDA approval of its brand new daxibotulinumtoxinA.
So let’s get started!
This is one of a host of new toxins. We have covered Alluzience - another new toxin whose USP is that it are reported to last approximately six months in duration, rather than the average three of other products. We have also covered Nuceiva, a toxin or “Newtox” made of a similar molecule to Botox itself and Letybo, based on the market leader in Asia. Refer to our Basics of Botox article to get the full summary.
So what should you know about Daxxify?
Daxxify [daxibotulinumtoxinA] is a long-awaited botulinum toxin type A launched by Revance Therapeutics. (It has been so anticipated it has often just been referred to by the company name: Revance!)
It has just received FDA approval in September 2022, which was delayed from 2020 due to the COVID-19 pandemic and several adjustments required by the FDA. It hasn’t been an easy road! However, it has already received a lot of favourable press in places like Glamour and Self.
It will likely become available in the States in 2023. No word yet on when it will arrive in the UK.
What is the research behind it?
Researchers conducted phase III trials that enrolled a total of >2700 subjects 4200 treatments in total, looking specifically at the frown lines. In the study, daxibotulinumtoxiNA was superior to a placebo, and was deemed effective and safe.
What makes it different?
Its primary differentiator, similar to Alluzience, is that it is meant to last much longer than its competitors - up to six months rather than the usual three! In some patients, it lasted up to nine months. As well as lasting longer, Daxxify can also be stored at room temperature.
References
Green JB, Mariwalla K, Coleman K, Ablon G, Weinkle SH, Gallagher CJ, Vitarella D, Rubio RG. A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study. Dermatol Surg. 2021 Jan 1;47(1):42-46. doi: 10.1097/DSS.0000000000002463. PMID: 32773447; PMCID: PMC7752221.
Galderma has unveiled Relfydess™ (RelabotulinumtoxinA), the world’s first ready-to-use liquid neuromodulator developed with proprietary PEARL™ Technology. This groundbreaking product has recently received approval for use in Europe. So what is it, and what sets it apart from the other toxins?.